Shares in Danish drugmaker Novo Nordisk fell by as much as 15%, after it was hit hard by U.S. regulators’ demands for further clinical testing of its new long-acting insulin drug Tresiba. Joanna Partridge reports
Thanks for checking us out. Please take a look at the rest of our videos and articles.
To stay in the loop, bookmark our homepage.